SynAct Pharma
12.5
SEK
-0.64 %
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
-0.64%
+40.45%
+50.6%
+78.7%
+41.56%
+84.37%
-90.95%
+26.85%
+168.73%
synactpharma.com/en
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SYNACT
Daily low / high price
11.96 / 12.95
SEK
Market cap
516.21M SEK
Turnover
897.03K SEK
Volume
73K
Latest videos
Financial calendar
Extraordinary general meeting
2024-12-13
Annual report
2025-02-18
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Sanos Group NBCD | 9.6 % | 9.6 % |
| Avanza Pension | 6.8 % | 6.8 % |
| Thomas Jonassen | 6.2 % | 6.2 % |
| Thomas Ringberg | 5.5 % | 5.5 % |
| Nordnet Pensionsförsäkring | 4.6 % | 4.6 % |
| Thomas von Koch | 2.7 % | 2.7 % |
| Torbjörn Bjerke | 1.9 % | 1.9 % |
| Handelsbanken Fonder | 1.9 % | 1.9 % |
| Kenneth Bjerg-Nielsen | 1.6 % | 1.6 % |
| OR Invest A/S | 1.0 % | 1.0 % |
ShowingAll content types
Valberedning utsedd inför årsstämma 2025 i SynAct Pharma AB
Nomination committee appointed ahead of AGM 2025 in SynAct Pharma AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioStock: Nya investerare och storägare backar SynActs kapitalanskaffning - vd kommenterar
BioStock: New and larger shareholders back SynAct's capital raise - CEO comments
SynAct Pharma erhåller EU-godkännande för fas 2b-studien ADVANCE med resomelagon (AP1189)
SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
Kallelse till extra bolagsstämma i SynAct Pharma AB
Notice of extraordinary general meeting in SynAct Pharma AB
SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
SynAct Pharma avser att genomföra riktade nyemissioner om totalt cirka 45 mkr och en fullt garanterad företrädesrättsemission om totalt cirka 20 mkr
SynAct Pharma presenterar positiva kliniska data för resomelagon (AP1189) på ACR Convergence som stödjer utveckling inom RA
SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
SynAct Pharma publicerar delårsrapport Q3 2024
SynAct Pharma publishes Q3 2024 interim results
SynAct Pharma medverkar på BIO-Europe i Stockholm 4-6 november
SynAct Pharma to attend BIO-Europe in Stockholm November 4-6
SynAct Pharmas ordförande till BioStock: "Vi är övertygade om att vi har rätt strategi"
SynAct Pharma's Chairman to BioStock: "We are confident we have the right strategy"
